Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug;26(4):253-265.
doi: 10.3747/co.26.5421. Epub 2019 Aug 1.

Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma

P Skrabek  1 , S Assouline  2 , A Christofides  3 , D MacDonald  4 , A Prica  5 , R Sangha  6 , B A Matthews  7 , L H Sehn  8
Affiliations
Review

Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma

P Skrabek et al. Curr Oncol. 2019 Aug.

Abstract

Diffuse large B cell lymphoma (dlbcl) is an aggressive non-Hodgkin lymphoma, accounting for approximately 30% of lymphoma cases in Canada. Although most patients will achieve a cure, up to 40% will experience refractory disease after initial treatment, or relapse after a period of remission. In eligible patients, salvage therapy followed by high-dose therapy and autologous stem-cell transplantation (asct) is the standard of care. However, many patients are transplant-ineligible, and more than half of those undergoing asct will subsequently relapse. For those patients, outcomes are dismal, and novel treatment approaches are a critical unmet need. In this paper, we present available data about emerging treatment approaches in the latter setting and provide a perspective about the potential use of those approaches in Canada.

Keywords: Diffuse large B cell lymphoma; dlbcl; non-Hodgkin lymphoma; novel therapies.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: Medical writing support provided by Anna Christofides of impact Medicom Inc. was funded by Hoffmann–La Roche Canada Inc. SA has received honoraria for consulting purposes from Janssen, Gilead, and Hoffmann–La Roche. DM has received honoraria for consulting purposes from Hoffmann–La Roche/Genentech, AbbVie, Amgen, AstraZeneca, Celgene, Gilead, Janssen, Lundbeck, Merck, and Seattle Genetics. AP has received honoraria for consulting purposes from AstraZeneca and AbbVie. RS has received honoraria for consulting purposes from Pfizer, Boehringer Ingelheim, AstraZeneca, Hoffmann–La Roche/Genentech, Lundbeck, Eli Lilly, Bristol–Myers Squibb, Merck, AbbVie, Novartis, and Takeda. BAM is an employee of Hoffmann–La Roche Canada Inc. LHS has received honoraria for consulting purposes from Hoffmann–La Roche/Genentech, AbbVie, Amgen, Apobiologix, AstraZeneca, Acerta Pharma, Celgene, Gilead, Janssen, Kite, Karyopharm, Lundbeck, Merck, MorphoSys, Seattle Genetics, Teva, Takeda, TG Therapeutics, and Versatem Oncology. She has also received research funding from Hoffmann–La Roche/Genentech. PS has no conflicts to disclose.

Figures

FIGURE 1
FIGURE 1
Selection of published papers in relapsed or refractory diffuse large B cell lymphoma. ASCT = autologous stem-cell transplantation; NHL = non-Hodgkin lymphoma; DLBCL = diffuse large B cell lymphoma; ORR = overall response rate.
See this image and copyright information in PMC

References

    1. Lymphoma Canada. Non-Hodgkin Lymphoma [Web page] Mississauga, ON: Lymphoma Canada; n.d.. [Available at: https://www.lymphoma.ca/lymphoma/non-hodgkinlymphoma; cited 11 March 2019]
    1. Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2018. Toronto, ON: Canadian Cancer Society; 2018.
    1. Lymphoma Canada. Diffuse Large B cell Lymphoma (DLBCL) [Web page] Mississauga, ON: Lymphoma Canada; n.d.. [Available at: https://www.lymphoma.ca/DLBCL; cited 10 January 2019]
    1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;9:717–20. doi: 10.1023/A:1008265532487. - DOI - PubMed
    1. Sarkozy C, Sehn LH. Management of relapsed/refractory dlbcl. Best Pract Res Clin Haematol. 2018;31:209–16. doi: 10.1016/j.beha.2018.07.014. - DOI - PubMed

MeSH terms

LinkOut - more resources